Patents by Inventor Yune Z. Kunes

Yune Z. Kunes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11965032
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: February 10, 2023
    Date of Patent: April 23, 2024
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Patent number: 11884740
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: January 30, 2024
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Patent number: 11814439
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: November 14, 2023
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes, Sri Hari Pandurang Miskin, Michael Weiss, Peter Sportelli
  • Patent number: 11807689
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: November 7, 2023
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Publication number: 20130243789
    Abstract: Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins.
    Type: Application
    Filed: January 11, 2013
    Publication date: September 19, 2013
    Applicant: Abbott Laboratories
    Inventors: Gerald R. Carson, Jochen G. Salfeld, Dean A. Regier, Jijie Gu, Wendy Gion, Yune Z. Kunes
  • Patent number: 8410259
    Abstract: Compositions and methods comprising recombinant expression vector elements (rEVEs) to enhance the level of expression of recombinant proteins are described. Other compositions and methods for lowering, substantially suppressing, or essentially silencing expression of a recombinant protein are also described.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: April 2, 2013
    Assignee: AbbVie Inc.
    Inventors: Wendy R. Gion, Gerald R. Carson, Hong Gao, Yune Z. Kunes
  • Publication number: 20110201053
    Abstract: Compositions and methods comprising recombinant expression vector elements (rEVEs) to enhance the level of expression of recombinant proteins are described. Other compositions and methods for lowering, substantially suppressing, or essentially silencing expression of a recombinant protein are also described.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 18, 2011
    Inventors: WENDY R. GION, GERALD R. CARSON, HONG GAO, YUNE Z. KUNES
  • Publication number: 20110150861
    Abstract: Embodiments of the invention relate to vector constructs and methods for expression of polypeptides including multimeric products such as therapeutic antibodies. Particular constructs allow for the generation of expression products from a single open reading frame (sORF). An embodiment provides an isolated or purified expression vector for generating one or more recombinant protein products comprising a single open reading frame insert; said insert comprising a signal peptide nucleic acid sequence encoding a signal peptide; a first nucleic acid sequence encoding a first polypeptide; a first intervening nucleic acid sequence encoding a first protein cleavage site, wherein said first protein cleavage site is provided by an intein segment of a Ion protease gene of Pyrococcus or a klbA gene of Pyrococcus or Methanococcus, or a modified intein segment derived therefrom; and a second nucleic acid sequence encoding a second polypeptide.
    Type: Application
    Filed: October 28, 2010
    Publication date: June 23, 2011
    Applicant: Abbott Laboratories
    Inventors: Gerald R. Carson, Wendy R. Gion, Yune Z. Kunes, Walter F. Leise, III, Rachel A. Davis-Taber, Emma Fung
  • Patent number: 7935808
    Abstract: Compositions and methods comprising recombinant expression vector elements (rEVEs) to enhance the level of expression of recombinant proteins are described. Other compositions and methods for lowering, substantially suppressing, or essentially silencing expression of a recombinant protein are also described.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: May 3, 2011
    Assignee: Abbott Laboratories
    Inventors: Wendy R. Gion, Gerald R. Carson, Hong Gao, Yune Z. Kunes
  • Publication number: 20110034368
    Abstract: Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. The primary product can also contain cleavage sequences such as other proteolytic cleavage or protease recognition sites, or signal peptides which contain recognition sequences for signal peptidases, separating at least two of the multiple protein subunits. The sequences of the inserted auto-processing polypeptides or cleavage sites can be manipulated to enhance the efficiency of expression of the separate multiple protein subunits.
    Type: Application
    Filed: June 24, 2010
    Publication date: February 10, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Gerald R. CARSON, Jochen G. SALFELD, Dean A. REGIER, Jijie GU, Wendy GION, Yune Z. KUNES
  • Publication number: 20080241883
    Abstract: Compositions and methods comprising recombinant expression vector elements (rEVEs) to enhance the level of expression of recombinant proteins are described. Other compositions and methods for lowering, substantially suppressing, or essentially silencing expression of a recombinant protein are also described.
    Type: Application
    Filed: March 28, 2008
    Publication date: October 2, 2008
    Inventors: Wendy R. Gion, Gerald R. Carson, Hong Gao, Yune Z. Kunes